A study looking at preventing late breast cancer recurrence in women who have had 5 years of hormone therapy (IBIS 3 feasibility)

This study tried to find out if an aromatase inhibitor, zoledronic acid and metformin on their own or in combinations could help stop breast cancer coming back.

It was for women after the menopause who:

• had no signs of breast cancer after 5 years of hormone therapy

• had an increased risk of their breast cancer coming back

Before researchers could run this study, they looked at how possible it was to do it well. This is called a feasibility study.

Cancer Research UK supported this study.